Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Events

26 Oct 2026 - 29 Oct 2026
16 Nov 2026 - 19 Nov 2026

Green Tea Found to Kill Leukemia Cells

By HospiMedica staff writers
Posted on 05 Apr 2004
Researchers using laboratory cell cultures have shown that a component of green tea known as epigallocatechin-3 gallate (EGCG) helps kill leukemia cells by interrupting the communication signals needed for them to survive.

The cells studied were from patients with B-cell chronic lymphocytic leukemia (CLL), which is most-often diagnosed in patients in their mid-to-late sixties. More...
Currently, there is no cure, although chemotherapy is administered in severe cases. In the study, green tea's EGCG interrupted survival signals prompted leukemia cells to die in eight of 10 patient samples tested.

While the rationale has been to spare elderly patients exposure to toxic chemotherapy, new tests have improved the ability of doctors to identify early-stage patients who have a more aggressive form of the cancer. As a result, much CLL research is now focused on identifying which initial-stage patients should be treated earlier in the course of the disease, as reported in the February 2004 issue of the journal Blood.

The researchers focused on green tea because epidemiologic studies of cancer have shown that in parts of the world where green tea is consumed, the incidence of solid tumor cancers such as breast, lung, and gastrointestinal cancer is lower. Also, mouse-model testing of the cancer-prevention properties of green tea have shown they protect against solid tumors. In addition, the EGCG component of green tea has been shown in the laboratory to induce death in cancer cells from solid tumors. Research suggests that EGCG works by inhibiting a pathway in the leukemia cells related to angiogenesis.

"We're continuing to look for therapeutic agents that are nontoxic to the patient but kill cancer cells, and this finding with EGCG is an excellent start,” said Neil E. Kay, M.D., of the Mayo Clinic (Rochester, MN, USA).




Related Links:
Mayo Clinic

Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Patient Preoperative Skin Preparation
BD ChloraPrep
Vessel Sealing Instrument
ERGOseal
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image:The NCIBT team with the cath lab members celebrating the completion of the study. (Image Credit: UC Davis)

Dual-Imaging Catheter Completes Initial Human Evaluation of Coronary Plaque

Atherosclerosis involves plaque buildup in arterial walls that can narrow blood vessels and increase the risk of heart attack, stroke, and other serious cardiovascular conditions. In coronary arteries,... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.